Recently Completed Protocols

1. **BMS Belatacept Steroid Withdrawal**
   Protocol No. IM103-034
   PI: Dr. Sander Florman
   Title: A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept-Based Corticosteroid-Free Regimens in Renal Transplant

2. **Roche Tamiflu Prophlaxis**
   Protocol No. NV2023
   PI: Dr. Brent Alper
   Title: A double blind, randomized, placebo controlled, multi-center trial of oseltamivir for the seasonal phrophylaxis of influenza in immunocompromised patients

3. **BMS Belatacept**
   Protocol Number: IM103008
   PI: Dr. Sander Florman
   Title: Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT)

4. **Y's Therapeutics**
   Protocol: YSPSL-0001.PF
   PI: Dr. Douglas Slakey
   Title: A Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Intravenous, Single-Dose, Dose-Escalating Study of the Safety, Pharmacokinetics, and Efficacy of YSPSL for Prevention of Delayed Graft Function in Patients Undergoing Cadaveric Kidney Tranplantation

5. **Wyeth Rapamune**
   Protocol No. 0468H1-101164 (S0478)
   PI: Dr. Douglas Slakey
   Title: An Open-Label, Concentration-Controlled Randomized 12 Month Study of Prograf + Rapamune + Corticosteroids Compared to Cyclosporine Capsules USP (Modified) + Rapamune + Corticosteroids in High Risk Renal Allograft Recipients

6. **Novartis MyTime Myfortic**
   Protocol CERL080AUS02 (S0575)
   PI: Dr. Douglas Slakey
   Title: A Three-Month, Open-Label, Two Cohort Study to Evaluate the Safety and Tolerability of Myfortic in Combination with Neoral or Tacrolimus in Renal Transplant Recipients with GI Intolerance

7. **Pfizer JAK3**
   Protocol Number A3921009 (S0585)
   PI: Dr Douglas Slakey
   Title: A 6-Month, Phase 2, Multicenter, Randomized, Open-Label, Comparative Study of 2 Dose Levels of CP-690,550 Administered Concomitantly with IL-2 Receptor Antagonist Induction Therapy, Mycophenolate Mofetil and Corticosteroids versus a Tacrolimus-Based Immunosuppressive Regimen for the Prevention of Allograft Rejection in De Novo Renal Allograft Recipients